ICG, TPG and CVC Secondary Partners led an investment in Curium.

ICG, TPG and CVC Secondary Partners, a private equity firms, led an investment in Curium, a company producer of radiopharmaceuticals, with participation from Goldman Sachs Alternatives, Lunate, Pantheon, and Ardian. Financial terms are not disclosed. “We are delighted to have successfully agreed this transaction with our partners at CapVest in record time. We are also proud to have received such strong investor interest, which endorses our unique positioning as the largest independent platform in nuclear medicine, with strong end-to-end capabilities across development, manufacturing, logistics and market access. This transaction positions us to accelerate the roll-out of our ambitious global strategy and drive further product launches, innovation and growth – all true to our passion to deliver life-changing solutions for healthcare professionals and millions of patients around the world,” Renaud Dehareng, Curium CEO.